Adjuvant Composition with STING Agonist and Aluminium Hydroxide
Summary
The USPTO has published a patent application by GlaxoSmithKline Biologicals SA for an adjuvant composition comprising a STING agonist and an aluminum-based adjuvant. The application details immunogenic compositions and their use in immunizing subjects.
What changed
This document is a publication of a United States patent application (US20260083838A1) filed by GlaxoSmithKline Biologicals SA. The application describes an adjuvant composition containing a STING agonist and an aluminum-based adjuvant, along with its use in immunogenic compositions for subject immunization.
As this is a patent application publication, it does not impose new regulatory obligations or compliance deadlines on regulated entities. However, it signals potential future developments in vaccine adjuvant technology, which may be of interest to pharmaceutical and biotechnology companies involved in drug development and manufacturing.
Archived snapshot
Mar 27, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Adjuvant Composition Comprising STING Agonists
Application US20260083838A1 Kind: A1 Mar 26, 2026
Assignee
GlaxoSmithKline Biologicals SA
Inventors
Kamelia BEHNIA, Dunja SOBOT, Laurent STRODIOT
Abstract
The present application relates to an adjuvant composition comprising:
(i) a STING agonist of Formula (I) or a pharmaceutically acceptable salt thereof
and
(ii) aluminium hydroxide, aluminium phosphate, aluminium oxyhydroxide, or aluminium hydroxy phosphate;
immunogenic compositions comprising the adjuvant composition, their use in methods of immunising a subject, and related aspects thereof.
CPC Classifications
A61K 39/39 A61K 39/25 A61P 31/22 A61P 37/04 A61K 2039/55505 A61K 2039/55511
Filing Date
2022-10-17
Application No.
18702442
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.